However, among the 13 patients with KRAS mutations in our study, none experienced tumor growth, and the pCR rate in patients undergoing surgery was 75% (6/8), which was comparable to the overall population and consistent with findings in the NICHE-2 study.31 The gene discussed is KRAS; the disease is neoplasm.